Vertebral fracture is usually the earliest clinical manifestation of severe osteoporosis. Early detection of vertebral fracture risk is therefore crucial for prevention and treatment of osteoporosis.
Vertebral fracture is usually the earliest clinical manifestation of severe osteoporosis. Early detection of vertebral fracture risk is therefore crucial for prevention and treatment of osteoporosis.
In this study we examined the ability of SOS measured at the distal third radius (Rad.), third proximal phalanx (PPIII) and mid-tibia (Tibia) to discriminate subjects with vertebral fractures from age matched controls and healthy young adult women. These measurements were performed by the Sunlight OmnisenseTM which enables bone evaluation at multiple skeletal sites using the Shortest Propagation Time principle of operation.
SOS measurements were performed on women with vertebral fractures (72±4 years old) and age matched control group of apparently healthy women (70±7 years old). T-Scores were calculated using data obtained by measuring about 150 healthy young adult women (40±3 years old).
The SOS at the Radius and Phalanx showed a significant discrimination between patients with vertebral fractures versus age matched control and healthy young women. At the tibial site no significant discrimination was detected.
Even though the data obtained was on a small sample size, statistically significant high OR values were observed. This presents a promising potential for the use of multi-site ultrasonic measurements as a diagnostic tool for the determination of vertebral fracture risk.
N
Fractured
N
Controls
Z Score
T Score
P
(t test)
P
(log.reg.)
ROC
OR (95% CI)
21
3855±155
79
3985±155
-0.85
-3.25
0.0006
0.0018
0.76
2.7
(1.5, 5.1)
14
3610±160
62
3765±180
-0.85
-2.35
0.0038
0.007
0.74
2.9
(1.4, 6.2)
24
3755±205
83
3760±160
-0.85
-1.30
0.88
0.88
N.S.
N.S.
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More
Hyperoxygenation use not linked to neonatal outcomes
April 23rd 2024Recent research evaluated the impact of maternal hyperoxygenation on neonatal Apgar scores, revealing no significant enhancement in outcomes among women with pathologic fetal heart rate tracing and suggesting limited efficacy of hyperoxygenation therapy in this context.
Read More
Study finds antihypertensive treatment reduces uterine fibroids risk
April 23rd 2024A recent study revealed that patients with untreated or new-onset hypertension face elevated chances of uterine fibroid diagnosis, underscoring the potential of antihypertensive therapy in mitigating this risk among midlife individuals.
Read More